【无锡/上海】近日，国内生物科技领域传来喜讯，专注于AI蛋白质设计与优化的无锡途深智合人工智能科技有限公司及其子公司上海途深生物科技有限责任公司（统称「途深智合」）成功获得数百万元的天使轮融资，投资方为诚美资本。这一轮融资将主要用于强化实验室设施建设和团队的扩充，以推动公司在人工智能蛋白质设计与制造领域的深度研发。
「途深智合」成立于2023年，是一家创新型生物科技企业，其主要业务是利用人工智能技术进行蛋白质设计与优化，为合成生物领域提供创新解决方案和新产品。在合成生物学的广阔舞台上，「途深智合」的出现有望打破传统模式，通过AI技术加速新药研发和生物制品的创新制造。
诚美资本的投资，不仅为「途深智合」的科研工作注入了资金活力，也将为其在生物科技与人工智能交叉领域的探索提供战略支持。随着实验室建设的推进和团队的不断壮大，「途深智合」将有望在蛋白质工程这一前沿科学领域取得更多突破，为我国的生物科技产业注入新的发展动力。
此次融资事件反映了资本市场对人工智能在生物技术应用前景的看好，也标志着「途深智合」在科技成果转化和商业化道路上迈出了坚实的一步。未来，「途深智合」将如何利用AI技术重塑蛋白质设计的未来，我们拭目以待。
英语如下：
**News Title:** “TuShen ZhiHe Secures Angel Investment, AI Protein Design Paves New Path in Biotechnology”
**Keywords:** TuShen ZhiHe, AI Proteins, Angel Financing
**News Content:** **Wuxi/Shanghai** – Recently, there was encouraging news in China’s biotechnology sector: Wuxi TuShen ZhiHe Artificial Intelligence Technology Co., Ltd. and its subsidiary Shanghai TuShen Biological Technology Co., Ltd. (collectively known as “TuShen ZhiHe”) successfully secured millions of yuan in an angel funding round, backed by Chengmei Capital. This funding will primarily be used to strengthen laboratory infrastructure and expand the team, advancing the company’s in-depth research and development in the field of artificial intelligence-driven protein design and manufacturing.
TuShen ZhiHe, founded in 2023, is an innovative biotech firm focusing on AI-assisted protein design and optimization, offering cutting-edge solutions and new products to the synthetic biology sector. On the broad canvas of synthetic biology, the company’s emergence is set to disrupt traditional models, leveraging AI technology to accelerate drug discovery and innovative bioproduct manufacturing.
The investment from Chengmei Capital not only infuses financial vitality into TuShen ZhiHe’s research endeavors but also provides strategic support for its exploration at the intersection of biotechnology and artificial intelligence. With the advancement of laboratory facilities and the growing team, TuShen ZhiHe is poised to make more breakthroughs in the frontier science of protein engineering, injecting new impetus into China’s biotechnology industry.
This funding round reflects the capital market’s optimism about the application prospects of AI in biotechnology and signifies a solid step for TuShen ZhiHe in translating scientific achievements into commercial ventures. As we await the future, it will be intriguing to see how TuShen ZhiHe utilizes AI technology to reshape the landscape of protein design.
【来源】https://36kr.com/p/2686282258132355
Views: 2